Glypican 1 Stimulates S Phase Entry and DNA Replication in Human Glioma Cells and Normal Astrocytes

REFERENCES

• Holland EC. 2000. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 97:6242–6244.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492–507.
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021.
   PubMed Web of Science ®Google Scholar
• Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature genetics. 25:55–57.
   PubMed Web of Science ®Google Scholar
• Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP. 2011. The origins of glioma: e pluribus unum? Glia 59:1135–1147.
   PubMed Web of Science ®Google Scholar
• Bonavia R, Inda MM, Cavenee WK, Furnari FB. 2011. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71:4055–4060.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683–2710.
   PubMed Web of Science ®Google Scholar
• Huse JT, Holland EC. 2010. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10:319–331.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110.
   PubMed Web of Science ®Google Scholar
• Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455:1129–1133.
   PubMed Web of Science ®Google Scholar
• Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A. 2006. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 168:2014–2026.
   PubMed Web of Science ®Google Scholar
• Fico A, Maina F, Dono R. 2011. Fine-tuning of cell signaling by glypicans. Cell. Mol. Life Sci. 68:923–929.
   PubMedGoogle Scholar
• Jen YH, Musacchio M, Lander AD. 2009. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural development. 4:33.
   PubMed Web of Science ®Google Scholar
• Litwack ED, Ivins JK, Kumbasar A, Paine-Saunders S, Stipp CS, Lander AD. 1998. Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent. Dev. Dynam. 211:72–87.
   PubMed Web of Science ®Google Scholar
• Qiao D, Meyer K, Friedl A. 2012. Glypican-1 stimulates Skp2 autoinduction loop and G1/S transition in endothelial cells. J. Biol. Chem. 287:5898–5909.
   PubMed Web of Science ®Google Scholar
• Qi W, Martinez JD. 2003. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res. 160:217–223.
   PubMed Web of Science ®Google Scholar
• Davidson IF, Li A, Blow JJ. 2006. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol. Cell 24:433–443.
   PubMed Web of Science ®Google Scholar
• Sclafani RA, Holzen TM. 2007. Cell cycle regulation of DNA replication. Annu. Rev. Genet. 41:237–280.
   PubMed Web of Science ®Google Scholar
• Symeonidou IE, Taraviras S, Lygerou Z. 2012. Control over DNA replication in time and space. FEBS Lett. 586:2803–2812.
   PubMedGoogle Scholar
• Ma D, Zhou P, Harbour JW. 2003. Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J. Biol. Chem. 278:19358–19366.
   PubMedGoogle Scholar
• Johnson DG, Walker CL. 1999. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39:295–312.
   PubMed Web of Science ®Google Scholar
• Yung Y, Walker JL, Roberts JM, Assoian RK. 2007. A Skp2 autoinduction loop and restriction point control. J. Cell Biol. 178:741–747.
   PubMedGoogle Scholar
• Starostina NG, Kipreos ET. 2012. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol. 22:33–41.
   PubMedGoogle Scholar
• Castro A, Bernis C, Vigneron S, Labbe JC, Lorca T. 2005. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24:314–325.
   PubMedGoogle Scholar
• Nakayama KI, Nakayama K. 2005. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 16:323–333.
   PubMed Web of Science ®Google Scholar
• Vodermaier HC. 2004. APC/C and SCF: controlling each other and the cell cycle. Curr. Biol. 14:R787–796.
   PubMed Web of Science ®Google Scholar
• Truong LN, Wu X. 2011. Prevention of DNA re-replication in eukaryotic cells. J. Mol. Cell Biol. 3:13–22.
   PubMed Web of Science ®Google Scholar
• Xouri G, Dimaki M, Bastiaens PI, Lygerou Z. 2007. Cdt1 interactions in the licensing process: a model for dynamic spatiotemporal control of licensing. Cell Cycle 6:1549–1552.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9:153–166.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Ortega S, Barbacid M. 2000. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 381:827–838.
   PubMedGoogle Scholar
• Caron C, Boyault C, Khochbin S. 2005. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27:408–415.
   PubMed Web of Science ®Google Scholar
• Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S. 2004. Novel aspects of glypican glycobiology. Cell. Mol. Life Sci. 61:1016–1024.
   PubMed Web of Science ®Google Scholar
• Liang Y, Haring M, Roughley PJ, Margolis RK, Margolis RU. 1997. Glypican and biglycan in the nuclei of neurons and glioma cells: presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle. J. Cell Biol. 139:851–864.
   PubMed Web of Science ®Google Scholar
• Asundi VK, Keister BF, Carey DJ. 1998. Organization, 5′-flanking sequence and promoter activity of the rat GPC1 gene. Gene 206:255–261.
   PubMedGoogle Scholar
• Lin H, Huber R, Schlessinger D, Morin PJ. 1999. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 59:807–810.
   PubMed Web of Science ®Google Scholar
• Boily G, Saikali Z, Sinnett D. 2004. Methylation analysis of the glypican 3 gene in embryonal tumours. Br. J. Cancer 90:1606–1611.
   PubMedGoogle Scholar
• Engelbert D, Schnerch D, Baumgarten A, Wasch R. 2008. The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogene 27:907–917.
   PubMed Web of Science ®Google Scholar
• Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. 2002. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr. Biol. 12:1817–1827.
   PubMed Web of Science ®Google Scholar
• Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A. 2003. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 11:997–1008.
   PubMed Web of Science ®Google Scholar
• Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S, Malumbres M. 2008. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 10:802–811.
   PubMed Web of Science ®Google Scholar
• Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797–802.
   PubMed Web of Science ®Google Scholar
• Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE, Roberts JM. 2005. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8:35–47.
   PubMedGoogle Scholar
• Seo J, Chung YS, Sharma GG, Moon E, Burack WR, Pandita TK, Choi K. 2005. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene 24:8176–8186.
   PubMed Web of Science ®Google Scholar
• Maddalena AS, Hainfellner JA, Hegi ME, Glatzel M, Aguzzi A. 1999. No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathol. 9:627–637.
   PubMedGoogle Scholar
• Huse JT, Holland EC. 2009. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 19:132–143.
   PubMed Web of Science ®Google Scholar